Αποτελέσματα Αναζήτησης
Reimbursement. Download Medicare Reimbursement Guide. If you have questions related to Cardiolite ® reimbursement, please call (800) 362-2668 (Option 3) or email reimbursement@lantheus.com. Lantheus cannot guarantee coverage or payment for products or procedures.
- Two Day Stress/Rest
Two Day Stress/Rest - Reimbursement - Cardiolite
- Risk Stratification
§The indications for Cardiolite ® are not specific to...
- Imaging Protocols
Imaging Protocols. Suggested Cardiolite ® One-Day...
- Prescribing Information
Prescribing Information - Reimbursement - Cardiolite
- Perfusion and Function
Myocardial Perfusion and Function assessed by a Gated...
- Patients
Patients - Reimbursement - Cardiolite
- Two Day Stress/Rest
CARDIOLITE® is a myocardial perfusion agent indicated for: detecting coronary artery disease by localizing myocardial ischemia (reversible defects) and infarction (non-reversible defects) evaluating myocardial function and developing information for use in patient management decisions.
25 Μαρ 2024 · Myocardial Imaging: CARDIOLITE ®, Kit for the Preparation of Technetium Tc99m Sestamibi for Injection, is a myocardial perfusion agent that is indicated for detecting coronary artery disease by localizing myocardial ischemia (reversible defects) and infarction (non-reversible defects), in evaluating myocardial function and developing ...
Myocardial Imaging: Cardiolite ® (Kit for the Preparation of Technetium Tc99m Sestamibi for Injection), is a myocardial perfusion agent that is indicated for detecting coronary artery disease by localizing myocardial ischemia (reversible defects) and infarction (non-reversible defects), in evaluating myocardial function and developing ...
Gated SPECT is recommended whenever feasible. For 99mTc, the most commonly used protocols are a. d, low-dose rest and high-dose stress protocol (Table. 3) or a 2-d protocol (for patients with a high body mass index) with equal radiotracer injection (925–1,110 MBq [25–30 mCi] of 99mTc) (5).
CARDIOLITE® is a myocardial perfusion agent indicated for: 1 detecting coronary artery disease by localizing myocardial ischemia (reversible defects) and infarction (non-reversible defects), 2 evaluating myocardial function and developing information for use in patient management decisions .
CARDIOLITE® is a myocardial perfusion agent indicated for: detecting coronary artery disease by localizing myocardial ischemia (reversible defects) and infarction (non-reversible defects) evaluating myocardial function and developing information for use in patient management decisions.
